News Sanofi beats expectations, driven by rare diseases and vacci... But sales of key insulin fall amid biosimilar competition.
News Report links Sanofi epilepsy drug with thousands of birth de... Depakine and generics linked with defects including spina bifida.
Views & Analysis Disruptive innovation, integrated care the only way forward,... Peter Guenter, head of Sanofi’s Diabetes & Cardiovascular business, on the future of chronic disease care.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
